TL;DR
The TFAP4-CDK1 axis is established as a critical driver of malignant progression in CRC and Targeting this pathway could lead to the development of novel interventions for CRC.
A seven-gene immune-related prognostic signature that, combined with clinicopathological parameters, provides a robust tool for individualized survival prediction and may guide precision management in CRC patients is developed and validated.
The CDRS performed well in predicting patient outcomes and showed strong prognostic validity, and differences in pathways enrichment, immune infiltration, drug sensitivity, and other factors between high risk and low risk groups based on CDRS scores were observed.
EZH2, CDK1, and AURKA constitute an internally validated prognostic risk signature in PCa that links cell cycle dysregulation to an immunosuppressive tumor microenvironment and provides clinically actionable risk stratification and highlights candidate therapeutic targets in prostate cancer.
This study identified five lung cancer-associated hub genes and provided preliminary evidence that resveratrol may modulate their expression, and provides a multi-level molecular framework for further investigation of resveratrol-responsive networks in lung cancer.
Investigation of MS-related prognostic genes and their potential biological relevance in CRC progression finds potential clues for future studies of CRC prognosis and MS-related tumor biology.
Three central apoptosis-related genes are identified as pivotal genes bridging psoriasis and IBD through apoptosis-related mechanisms, shed light on the shared molecular underpinnings of these comorbid conditions and highlight potential targets for future therapeutic strategies.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
